Open Label, Non-randomized, Phase 2 Study Investigating the Effect of RAD001 Monotherapy in Patients With Advanced NSCLC Previously Treated With Either Chemotherapy Only or With Chemotherapy and EGFR Inhibitor(s)
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical efficacy based on the evaluation of objective tumor response rate (RR)
until progressive disease or unacceptable toxicity.
United States: Food and Drug Administration
|Nevada Cancer Institute||Las Vegas, Nevada 89135|
|MD Anderson Cancer Center, Department of Thoracic /Head and Neck Medical Oncology||Houston, Texas 77030|